KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) Gross Margin (2017 - 2025)

BeOne Medicines (ONC) has disclosed Gross Margin for 9 consecutive years, with 90.49% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin rose 473.0% to 90.49% in Q4 2025 year-over-year; TTM through Dec 2025 was 87.49%, a 308.0% increase, with the full-year FY2025 number at 87.49%, up 308.0% from a year prior.
  • Gross Margin was 90.49% for Q4 2025 at BeOne Medicines, up from 86.09% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 94.61% in Q1 2021 to a low of 75.82% in Q2 2021.
  • A 5-year average of 83.34% and a median of 83.35% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: surged 2178bps in 2021, then plummeted -1588bps in 2022.
  • BeOne Medicines' Gross Margin stood at 77.31% in 2021, then rose by 4bps to 80.66% in 2022, then increased by 3bps to 83.32% in 2023, then increased by 3bps to 85.76% in 2024, then increased by 6bps to 90.49% in 2025.
  • Per Business Quant, the three most recent readings for ONC's Gross Margin are 90.49% (Q4 2025), 86.09% (Q3 2025), and 87.49% (Q2 2025).